(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of 184.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Dare Bioscience's revenue in 2026 is $1,365,939.On average, 4 Wall Street analysts forecast DARE's revenue for 2026 to be $48,207,800, with the lowest DARE revenue forecast at $7,222,149, and the highest DARE revenue forecast at $91,507,669. On average, 4 Wall Street analysts forecast DARE's revenue for 2027 to be $115,236,977, with the lowest DARE revenue forecast at $80,346,333, and the highest DARE revenue forecast at $151,182,596.
In 2028, DARE is forecast to generate $540,483,896 in revenue, with the lowest revenue forecast at $361,122,748 and the highest revenue forecast at $725,838,528.